Insulin: the central metabolic hormone
Insulin is among the most thoroughly researched hormones in the human body, and it is itself a peptide hormone – built from amino acid chains, just like many of the substances discussed in the peptide community. It is produced in the beta cells of the pancreas and is the body's most important internal regulator of blood sugar. This article explains what insulin does physiologically, how blood sugar is regulated, and why the modern GLP-1 and incretin peptides act precisely through insulin secretion. The text is purely educational: it describes mechanisms and evidence but gives no application or dosing guidance. Insulin is a prescription medicine; all questions about diagnosis and therapy belong in the hands of a physician.
Machine-assisted translation. The German original is the authoritative version.
Key points
- Insulin is itself a peptide hormone, produced in the beta cells of the pancreas, and the body's most important internal regulator of blood sugar.
- It lowers blood sugar by promoting glucose uptake into cells, letting the liver store sugar and reining in its counterpart glucagon.
- GLP-1/incretin peptides such as semaglutide act one step earlier: they amplify the body's own blood-sugar-dependent insulin secretion rather than replacing insulin.
- Insulin is a prescription-only, very well studied medicine and not a lifestyle product; hypoglycemia is a serious risk.
- All questions about blood sugar, diabetes or hormone therapy belong in medical evaluation – this text is no substitute for advice.
What insulin is – a peptide hormone from the pancreas
Insulin is a peptide hormone produced by the beta cells of the islets of Langerhans in the pancreas and released into the blood. Chemically, it consists of two short amino acid chains – an A and a B chain – linked together by sulfur bridges. In the beta cell it first arises as a larger precursor molecule (proinsulin), which is then processed into the finished insulin; in this step the so-called C-peptide is cleaved off, which can be measured in the laboratory as an indicator of the body's own insulin production.
Because insulin is itself built from amino acids, it cannot simply be swallowed as a tablet – it would be broken down in the digestive tract. That explains why medical insulin is injected. Insulin is thus a good example of the fact that „peptide“ does not automatically mean „experimental“: it is one of the oldest and most thoroughly studied hormone preparations in modern medicine and appears on the WHO list of essential medicines.
- Peptide hormone made of two amino acid chains (A and B chain)
- Produced in the beta cells of the islets of Langerhans in the pancreas
- Arises from the precursor proinsulin; C-peptide is cleaved off in the process
- Is injected because, as a protein molecule, it would be broken down in the gastrointestinal tract
How insulin regulates blood sugar
Insulin's central task is to lower the blood sugar level. After a carbohydrate-containing meal, glucose in the blood rises; the beta cells register this and secrete insulin. Insulin binds to its receptors on the body's cells – they are especially dense on liver, muscle and fat cells. Among other things, this binding causes glucose transporters to move to the cell surface, so that sugar can be taken up from the blood into the cells.
At the same time, insulin steers metabolism in several organs: in the liver it promotes the storage of glucose as glycogen and slows the body's own production of new sugar. In muscle and fat tissue it favors building-up rather than breaking-down processes. In the pancreas, insulin also inhibits the secretion of glucagon, its counterpart, which raises blood sugar. Insulin and glucagon thus form a finely tuned control system that keeps blood sugar within a narrow range.
- Is secreted when blood sugar rises after eating
- Promotes the uptake of glucose into muscle and fat cells
- Lets the liver store glucose and throttles the production of new sugar
- Inhibits glucagon, the blood-sugar-raising counterpart
The relationship to GLP-1 and incretin peptides
This is where the circle closes back to the metabolic peptides currently much discussed. After eating, the gut produces its own hormones, the so-called incretins – above all GLP-1 (Glucagon-like Peptide-1) and GIP. These incretins amplify insulin secretion by the beta cells, and predominantly when blood sugar is elevated. This „incretin effect“ explains why a quantity of glucose taken orally releases more insulin than the same quantity administered while bypassing the gut.
Modern medicines such as semaglutide mimic GLP-1. According to the European Medicines Agency EMA, semaglutide (in Ozempic) is a GLP-1 receptor agonist that increases insulin release from the pancreas in response to food; it is approved for the treatment of type 2 diabetes. These substances therefore do not replace insulin but act one step earlier: they stimulate the body's own blood-sugar-dependent insulin secretion and additionally influence appetite and gastric emptying. This makes it possible to understand why insulin and the GLP-1 peptides are indeed related metabolic topics yet have different modes of action.
- Incretins (GLP-1, GIP) are gut hormones released after eating
- They amplify insulin secretion, especially when blood sugar is elevated
- GLP-1 receptor agonists such as semaglutide mimic this effect (EMA-approved for type 2 diabetes)
- They do not replace insulin but stimulate the body's own secretion
Status, limits and an honest assessment
Insulin is a prescription-only, very well researched medicine with a clear indication: for people with type 1 diabetes it is, according to the WHO, essential for survival, while in type 2 diabetes it is one of several treatment options. It is not a lifestyle product or dietary supplement and belongs exclusively in medically supervised therapy. An excessively strong lowering of blood sugar (hypoglycemia) can become dangerous – which underlines why use, adjustment and monitoring must always be carried out by a physician.
For the peptide community, insulin is interesting above all as a physiological reference point: it shows how a peptide hormone steers metabolism, and it is the common denominator at which the GLP-1 effect takes hold. Claims from forums that one could deliberately „hack the metabolism“ or steer muscle growth via hormones like insulin are not substantiated medical statements but community claims – and improper handling of substances that affect blood sugar is potentially life-threatening. Anyone who notices symptoms such as persistent thirst, frequent urination or unexplained metabolic changes should have this medically clarified rather than experimenting on their own.
- Prescription medicine, not a dietary supplement
- Essential for survival in type 1 diabetes, one option among several in type 2
- Hypoglycemia is a serious risk – adjustment belongs in the hands of a physician
- Forum claims about „hacking the metabolism“ are not substantiated
Related substance profiles
Frequently asked questions
- Is insulin a peptide?
- Yes. Insulin consists of two short amino acid chains (A and B chain) and is therefore a peptide hormone. It is one of the longest and most thoroughly researched peptide hormones in medicine and appears on the WHO list of essential medicines.
- What does insulin have to do with GLP-1 medicines like semaglutide?
- GLP-1 is a gut hormone (incretin) that amplifies insulin secretion by the pancreas – especially when blood sugar is elevated. GLP-1 receptor agonists such as semaglutide mimic this effect. According to the EMA, they increase the body's own insulin release in response to food; they therefore do not replace insulin but stimulate its secretion.
- Can I infer from this article how insulin is used?
- No. This article is purely educational and describes only physiology and context. Insulin is prescription-only, and its adjustment – including the risk of dangerous hypoglycemia – belongs exclusively in the hands of a physician.
Sources
- StatPearls, NCBI BookshelfInsulin – Physiology and PharmacologyReference
- European Medicines Agency (EMA)Ozempic (semaglutide) – EPAR OverviewAuthority / regulatory
- Endotext, NCBI BookshelfInsulin – Pharmacology, Therapeutic Regimens and Principles of Intensive Insulin TherapyReference
- World Health Organization (WHO)Diabetes – Fact SheetAuthority / regulatory
This article is for information and education only. It does not replace medical advice and deliberately contains no dosing, usage or sourcing information.